Search results for "risk stratification"

showing 10 items of 71 documents

Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: Rationale and design of the HoT-PE Trial

2016

SummaryPulmonary embolism (PE) is a potentially life-threatening acute cardiovascular syndrome. However, more than 95 % of patients are haemodynamically stable at presentation, and among them are patients at truly low risk who may qualify for immediate or early discharge. The Home Treatment of Pulmonary Embolism (HoT-PE) study is a prospective international multicentre single-arm phase 4 management (cohort) trial aiming to determine whether home treatment of acute lowrisk PE with the oral factor Xa inhibitor rivaroxaban is feasible, effective, and safe. Patients with confirmed PE, who have no right ventricular dysfunction or free floating thrombi in the right atrium or ventricle, are eligib…

medicine.medical_specialtyAdministration OralHome treatment; Management trial; Pulmonary embolism; Risk stratification; Rivaroxaban; HematologySelf Administration030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeRivaroxabanRecurrenceRisk FactorsInternal medicinemedicineHumansProspective Studies030212 general & internal medicineIntensive care medicineProspective cohort studyEarly dischargeRisk stratificationRivaroxabanbusiness.industryPulmonary embolismHome treatmentManagement trialHematologymedicine.diseaseHome Care ServicesComorbidityPatient DischargePulmonary embolismCohortQuality of LifebusinessFactor Xa Inhibitorsmedicine.drug
researchProduct

D-dimer for risk stratification in haemodynamically stable patients with acute pulmonary embolism

2015

Patients with submassive pulmonary embolism (PE) have a higher short-term mortality than those with low-risk PE. Rapid identification of submassive PE is important for adequate treatment of non-massive PE. We aimed to investigate the utility of D-dimer for the prediction of submassive PE stadium in normotensive PE patients.Normotensive PE patients were classified into submassive or low-risk PE groups. In addition to the comparison of the groups, area under the curve (AUC) and D-dimer cut-off for the prediction of submassive PE stadium, multi-variate logistic regression for association between D-dimer values above this cut-off and submassive PE stadium were also calculated.The data of 129 no…

Malemedicine.medical_specialtyVentricular Dysfunction RightFibrin Fibrinogen Degradation ProductsTachycardiaInternal medicineHeart rateD-dimerHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overbusiness.industryArea under the curveGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismLogistic ModelsBlood pressureHaemodynamically stableRisk stratificationCardiologyFemalePulmonary EmbolismbusinessAdvances in Medical Sciences
researchProduct

Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review

2019

The clinical evolution of solitary fibrous tumor (SFT) remains unclear. Although various clinical, morphological and molecular criteria may indicate increased risk of malignancy, some SFT can still progress despite having a clearly benign appearance. Various risk stratification systems have been proposed, but unfortunately they are not sufficient to precisely determine the malignant potential. In this review, we discuss current knowledge on SFT, focusing on the following controversial issues: (i) the diverse morphologic spectrum: 'the great simulator;' (ii) malignant transformation or dedifferentiation; (iii) current risk stratification systems; and (iv) molecular factors associated with cl…

Risk0301 basic medicinePathologymedicine.medical_specialtySolitary fibrous tumorMalignancyPathology and Forensic MedicineMalignant transformationDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumansPathologicalbusiness.industrySoft tissueGeneral MedicineCell DedifferentiationPrognosismedicine.diseaseImmunohistochemistryCell Transformation Neoplastic030104 developmental biologyIncreased riskSolitary Fibrous Tumors030220 oncology & carcinogenesisRisk stratificationbusinessPathology International
researchProduct

Is proteomics of value in cardiovascular risk assessment?

2019

Purpose of review To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research. Recent findings Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candi…

0301 basic medicineProteomicsClinical variablesGrowth Differentiation Factor 15Endocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyProteomicsBioinformaticsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsGeneticsMedicineAnimalsHumansBiomarker discoveryNatriuretic PeptidesMolecular BiologyNutrition and Dieteticsbusiness.industryInterleukinsCell BiologyTargeted proteomics030104 developmental biologyC-Reactive ProteinCardiovascular DiseasesRisk stratificationMetalloproteasesCardiology and Cardiovascular MedicinebusinessRisk assessmentBiomarkersCurrent opinion in lipidology
researchProduct

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction

2015

Background Gene expression profiling is being widely applied in cancer research to identify biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for transcriptome-based applications beyond the limitations of microarrays, we sought to systematically evaluate the performance of RNA-seq-based and microarray-based classifiers in this MAQC-III/SEQC study for clinical endpoint prediction using neuroblastoma as a model. Results We generate gene expression profiles from 498 primary neuroblastomas using both RNA-seq and 44 k microarrays. Characterization of the neuroblastoma transcriptome by RNA-seq reveals that more than 48,000 genes and 200,000 transcripts are being …

AdultMaleMicroarrayAdolescentEndpoint DeterminationNEUROBLASTOMA PATIENTSgenetic processesRNA-SeqBiologyBioinformaticsRISK STRATIFICATIONTranscriptomeNeuroblastomaYoung AdultREPRODUCIBILITYClinical endpointTumor Cells CulturedBREAST-CANCERHumansnatural sciencesTRANSCRIPTOMEChildGENE-EXPRESSIONOligonucleotide Array Sequence AnalysisSettore BIO/11 - BIOLOGIA MOLECOLAREEXPRESSION-BASED CLASSIFICATIONModels GeneticSequence Analysis RNAGene Expression ProfilingResearchSIGNATUREInfant NewbornBiology and Life SciencesInfantHuman genetics3. Good healthPROSTATE-CANCERGene expression profilingDIFFERENTIATIONChild PreschoolEndpoint DeterminationFemaleDNA microarray
researchProduct

Use of QT intervals for a more accurate diagnose of syncope and evaluation of syncope severity.

2014

Abstract BACKGROUND: This study aimed to evaluate the use of QT intervals, their diagnostic predictive value in patients with syncope and their relationship with syncope severity. METHODS: One hundred and forty nine patients with a diagnosis of syncope were admitted to Internal Medicine departments at the University of Palermo, Italy, between 2006 and 2012, and 140 control subjects hospitalised for other causes were enrolled. QT maximum, QT minimum, QTpeak, QT corrected, QT dispersion and Tpeak-to-Tend interval were compared between two groups. The paper medical records were used for scoring with San Francisco Syncope Rule (SFSR), Evaluation of Guidelines in SYncope Study (EGSYS) score and …

MaleSan Francisco Syncope Rulemedicine.medical_specialtySettore MED/09 - Medicina InternaSettore MED/42 - Igiene Generale E ApplicataTHERAPYQT intervalSyncopeRISK STRATIFICATIONElectrocardiographyPROSPECTIVE VALIDATIONDISPERSIONRisk FactorsInternal medicineSCOREmedicineHumansIn patientPREDICT PATIENTSAgedAged 80 and overFramingham Risk ScoreSERIOUS OUTCOMESmedicine.diagnostic_testbiologybusiness.industryMedical recordVENTRICULAR REPOLARIZATION; PROSPECTIVE VALIDATION; RISK STRATIFICATION; DIABETIC-PATIENTS; SERIOUS OUTCOMES; PREDICT PATIENTS; DISPERSION; GENDER; THERAPY; SCORESyncope (genus)General MedicineMiddle AgedControl subjectsbiology.organism_classificationDIABETIC-PATIENTSItalyAnesthesiaCardiologyFemaleGENDERVENTRICULAR REPOLARIZATIONbusinessElectrocardiography
researchProduct

Rationale, design and methods of CTCA-PRORECAD (Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease): a multicen…

2013

PURPOSE: This study was done to assess the prognostic value of computed tomography coronary angiography (CTCA) in a large multicentre population of patients with suspected coronary artery disease (CAD) and, in particular, its incremental value compared with traditional methods for risk stratification. MATERIALS AND METHODS: This is a retrospective observational study that began in January 2003 conducted on patients with suspected CAD assessed with CTCA on the basis of symptoms (chest pain, dyspnoea) and/or abnormal or equivocal stress test and/or a high cardiovascular risk profile. The participating centres will provide data obtained with CTCA performed with 16-slice or higher equipment. Ex…

Coronary angiographyMaleContrast MediaComputed tomographyCoronary DiseaseCoronary AngiographyCoronary artery diseaseComputed tomography coronary angiographyCoronary artery diseaseComputer-AssistedRisk FactorsRegistriesTomographyNeuroradiologyeducation.field_of_studymedicine.diagnostic_testcomputed tomography coronary angiography; coronary artery disease; prevalence of disease; prognosis; registry; risk stratificationRadiographic Image InterpretationInterventional radiologyGeneral MedicineMiddle AgedPrognosisX-Ray ComputedResearch DesignRisk stratificationCardiologyPrevalence of diseaseRadiographic Image Interpretation Computer-AssistedFemaleRadiologymedicine.medical_specialtyRegistryPrognosiEndpoint DeterminationPopulationRisk AssessmentComputed tomography coronary angiography; Coronary artery disease; Prevalence of disease; Prognosis; Risk stratification; Registry; Analysis of Variance; Contrast Media; Coronary Disease; Endpoint Determination; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiographic Image Interpretation Computer-Assisted; Retrospective Studies; Risk Assessment; Risk Factors; Coronary Angiography; Registries; Research Design; Tomography X-Ray ComputedInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingeducationRisk stratificationProportional Hazards ModelsRetrospective StudiesAnalysis of Variancebusiness.industrymedicine.diseasebusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

5877Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome

2019

Abstract Background The Charlson's is the most used comorbidity index. It comprises 19 comorbidities, some of which are infrequent in elderly patients with acute coronary syndrome (ACS), while some others are manifestations of cardiac disease rather than comorbidities. Purpose Our goal was to simplify comorbidity assessment in elderly non-ST-segment elevation ACS patients. Methods The study group consisted of 1 training (n=920, 76±7 years) and 1 testing (n=532; 84±4 years) cohorts. The end-point was all-cause mortality at 1-year follow-up. Comorbidities were assessed selecting those medical disorders other than cardiac disease that were independently associated with mortality by multivariab…

medicine.medical_specialtyAcute coronary syndromebusiness.industryInternal medicineRisk stratificationmedicineCardiology and Cardiovascular Medicinemedicine.diseasebusinessEuropean Heart Journal
researchProduct

Definition of tachycardia for risk stratification of pulmonary embolism

2020

Tachycardia is a reliable predictor of adverse outcomes in normotensive patients with acute pulmonary embolism (PE). However, different prognostic relevant heart rate thresholds have been proposed. The aim of the study was to investigate the prognostic performance of different thresholds used for defining tachycardia in normotensive PE patients.We performed a post-hoc analysis of normotensive patients with confirmed PE consecutively included in a single-centre and a multi-centre registry. An adverse outcome was defined as PE-related death, need for mechanical ventilation, cardiopulmonary resuscitation or administration of catecholamines.Of 1567 patients (median age: 72 [IQR, 59-79] years; f…

Tachycardiamedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineTachycardiaInternal medicineHeart rateInternal MedicineHumansMedicineIn patient030212 general & internal medicineCardiopulmonary resuscitationAgedMechanical ventilationbusiness.industryGuidelineMiddle AgedPrognosismedicine.diseasePulmonary embolismROC CurveRisk stratificationCardiologyFemalemedicine.symptomPulmonary EmbolismbusinessEuropean Journal of Internal Medicine
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct